Code is covered without prior authorization (high confidence)
Key Coverage Criteria
Autologous hematopoietic stem cell transplantation(AutoHSCT)for treatment of individuals with multiple myeloma is consideredmedically necessarywhen used as:
As a single transplant (AutoHSCT);or
As a tandem* transplant (two AutoHSCTs separated by 30 to 180 days);or
As a repeat procedure (AutoHSCT greater than 180 days following a previous AutoHSCT);or
As a pretreatment for a non-myeloablative allogeneic hematopoietic stem cell transplant;or
As salvage therapy after:Primary graft failure;orFailure to engraft;orRejection following an allogeneic HSCT.